Trials / Unknown
UnknownNCT01005121
Colchicine for Diabetic Nephropathy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Prof.Avi Livneh · Other Government
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function tests will be monitored. The investigators' hypothesis is that colchicine will diminish proteinuria and might also help slow down the development of end stage renal failure in the long run.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | colchicine | 2mg, per-os, once daily for six months |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2014-12-01
- Completion
- 2015-12-01
- First posted
- 2009-10-30
- Last updated
- 2013-01-04
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01005121. Inclusion in this directory is not an endorsement.